Impact of high-dose rate and low-dose rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study
AuthorsParry, M. G.
Cowling, T. E.
Patel, R. N.
Clarke, Noel W
van der Meulen, J.
AffiliationDepartment of Health Services Research and Policy, LSHTM; The National Prostate Cancer Audit, Clinical Effectiveness Unit, Royal College of Surgeons of England.
MetadataShow full item record
AbstractPurpose: External beam radiotherapy (EBRT) with brachytherapy boost reduces cancer recurrence in patients diagnosed with prostate cancer compared to EBRT monotherapy. However, randomised controlled trials or large-scale observational studies have not compared brachytherapy boost types directly. Methods and materials: This observational cohort study used linked national cancer registry data, radiotherapy data, administrative hospital data and mortality records of 54,642 patients diagnosed with intermediate-risk, high-risk and locally advanced prostate cancer in England. The records of 11,676 patients were also linked to results from a national patient survey collected at least 18 months after diagnosis. Competing risk regression analyses were used to compare gastrointestinal (GI) toxicity, genitourinary (GU) toxicity, skeletal-related events (SREs), and prostate cancer-specific mortality (PCSM) at five years with adjustment for patient and tumour characteristics. Linear regression was used to compare EPIC-26 domain scores (scale from 0 to 100, higher scores indicating better function). Results: 5-year GI toxicity was significantly increased after LDR-BB (32.3%) compared to HDR-BB (16.7%) or EBRT monotherapy (18.7%). 5-year GU toxicity was significantly increased after both LDR-BB (15.8%) and HDR-BB (16.6%), compared to EBRT monotherapy (10.4%). These toxicity patterns were matched by the mean patient-reported bowel function scores (LDR-BB: 77.3, HDR-BB: 85.8, and EBRT monotherapy: 84.4) and the mean patient-reported urinary obstruction/irritation function scores (LDR-BB: 72.2, HDR-BB: 78.9, and EBRT monotherapy: 83.8). 5-year incidences of SREs and PCSM were significantly lower after HDR-BB (2.4% and 2.7%, respectively) compared to EBRT monotherapy (2.8% and 3.5%, respectively). Conclusions: LDR-BB has worse GI and GU toxicity and HDR-BB has worse GU toxicity compared to EBRT monotherapy. HDR-BB has a lower incidence of SREs and PCSM than EBRT monotherapy.
CitationParry MG, Nossiter J, Sujenthiran A, Cowling TE, Patel RN, Morris M, et al. Impact of high-dose rate and low-dose rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study. Int J Radiat Oncol Biol Phys. 2020.
JournalInternational Journal of Radiation Oncology Biology Physics
- High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
- Authors: Yamazaki H, Masui K, Suzuki G, Nakamura S, Yamada K, Okihara K, Shiraishi T, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K
- Issue date: 2019 Mar
- Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
- Authors: Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H
- Issue date: 2005 Oct 1
- Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
- Authors: Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W
- Issue date: 2019 Mar
- A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate.
- Authors: Fischer-Valuck BW, Gay HA, Patel S, Baumann BC, Michalski JM
- Issue date: 2019
- ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
- Authors: Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N
- Issue date: 2017 Jun 1